

## DAY OF SCIENCE AND INNOVATION ABSTRACTS

### Imaging the Lymphatic Response to Manual Lymphatic Drainage and Pneumatic Compression Devices



**John Rasmussen,<sup>1</sup>** Caroline Fife,<sup>2,3</sup> Eva Sevick-Muraca,<sup>1</sup> <sup>1</sup>University of Texas Health Science Center at Houston; <sup>2</sup>CHI St Luke's-The Woodlands Hospitals; <sup>3</sup>Intellicure

**Objective:** Manual lymphatic drainage (MLD), as a component of complete decongestive therapy, has formed the basis of the initial treatment for lymphedema (LED), and pneumatic compression (PC) has been used in the maintenance phase (at-home treatment). The physiologic mechanism, however, of methods to promote lymph drainage for both MLD and PC has not been rigorously established. Recent developments in near-infrared fluorescence lymphatic imaging (NIRFLI) have enabled the visualization of the lymphatic response to these therapies nearly in real time and provide opportunities to assess the physiologic impact of these manual interventions. Herein we summarize the results of seven studies, published and unpublished, assessing the acute and longitudinal impact of MLD or PC therapy in patients with phlebolymphedema or standard arm, leg, or head and neck LED.

**Methods:** After informed consent and under Food and Drug Administration-approved investigational new drugs for off-label administration of indocyanine green (ICG) as an imaging agent for NIRFLI, we visualized lymphatic anatomy and contractile pumping activity in study participants. Patients received intradermal injections of ICG distal to the area of vascular interest, typically in the hands and feet. Imaging was performed by illuminating the skin with near-infrared light and collecting the fluorescent light emanating from the ICG-laden lymph. Whereas imaging times varied between each study, imaging was conducted immediately before and after treatment and, when possible, during treatment. In one study, NIRFLI was also performed before and after 2 weeks of PC therapy in patients with head and neck LED. Images were assessed for changes in lymphatic uptake and contractile pumping.

**Results:** Overall 69 patients, 51 affected and 18 control, undergoing MLD or PC therapy were imaged. The first study of 10 LED and 12 control patients showed a 23% and 28% increase in lymph velocity and a 9% and 23% reduction in propulsion period in symptomatic and control limbs, respectively, in response to MLD. Other NIRFLI studies demonstrated enhanced lymphatic uptake after PC therapy in control patients and patients diagnosed with phlebolymphedema or standard LED. One study, using a clear PC device, demonstrated the ability to image the statistically significant improvement in lymphatic contractile propulsion during and after PC therapy. A recent unpublished study of 10 patients with head and neck LED demonstrated enhanced lymphatic uptake in all patients and a reduction of abnormal lymphatic anatomy in 75% of patients after 2 weeks of daily at-home PC therapy.

**Conclusions:** NIRFLI enables the assessment of manual lymphatic interventions, demonstrating enhanced lymphatic uptake and improved lymphatic contractile pumping in response to MLD and PC therapy in patients with LED.

**Author Disclosures:** **J. Rasmussen:** research funding, honorarium Tactile Medical; **C. Fife:** Nothing to disclose; **E. Sevick-Muraca:** research funding, honorarium Tactile Medical.

### The Proportion and Causes of Lymphedema in a Large Administrative Insurance Database



**Andrew Son,<sup>1</sup>** Thomas O'Donnell,<sup>1</sup> Jessica Izhakoff,<sup>2</sup> Timothy Niecko,<sup>3</sup> Julia Gaebler,<sup>2</sup> Mark Iafrazi<sup>1</sup>. <sup>1</sup>Department of Surgery, Tufts Medical Center; <sup>2</sup>Health Advances, LLC; <sup>3</sup>Niecko Health Economics, LLC

**Objective:** Lymphedema (LED) has been called the forgotten vascular disease, given such limited knowledge about the prevalence of LED and in particular its associated comorbidities and causes. Such information on the proportion of patients with LED and its causes may assist in diagnostic decisions and health care planning.

**Methods:** To determine the proportion of patients with LED and the possible causes of LED, deidentified Health Insurance Portability and Accountability Act-compliant commercial administrative claims from

the Blue Health Intelligence (BHI) research database (165 million Blue Cross Blue Shield members) were queried. To identify the proportion affected with LED and the comorbidities (potential causes) associated with LED, we analyzed a BHI study sample of 26,902 patients with LED who had been enrolled with continuous medical benefits for 12 months before and after the index date for the complete years 2012 through 2016. It was the purpose of this study to analyze the BHI data set to determine the proportion of LED that occurs in a "real-world" setting and to identify the specific causes of LED.

**Results:** Overall, 84,579,269 patients were available for initial analysis, from which 81,366 patients (0.10%) were identified with LED. From the total population (42,229,536) within the BHI data set for women, 74,807 (0.18%) women were identified with LED; from the total population of men in the BHI data set (42,349,733), a lower number of men, 28,358 (0.07%), had LED. Based on an assessment of 26,902 eligible patients (determined by continuous enrollment criteria), breast cancer, which occurred in nearly 9000 patients (32.1%), was the most common comorbidity associated with LED. The category of venous disease as a whole accounted for 10.4% of patients with LED. Within that category, venous ulcer compromised the majority of the venous disease group (9.6%). The combined entity of pelvic cancers in women (uterine, ovarian, and cervical cancer) accounted for 3.3% of all causes of LED. Finally, melanoma was observed in 2.1% of patients with LED. Prostate cancer was a less frequent cause of LED, which was observed in 188 patients (0.7%). The sequelae of treating sex-specific cancer (breast and pelvic) in women accounted for >35% of patients with LED.

**Conclusions:** To our knowledge, this is the largest study to date providing the real-world proportion of patients with LED and detailing the causes of LED. Our findings confirm the major role of cancer, particularly breast cancer, as an important cause of LED. Furthermore, this study highlights the role of advanced venous disease as a cause of LED.

**Author Disclosures:** **A. Son:** Nothing to disclose; **T. O'Donnell:** consulting fee Tactile Medical; **J. Izhakoff:** Nothing to disclose; **T. Niecko:** consulting fee Tactile Medical; **J. Gaebler:** consulting fee Tactile Medical; **M. Iafrazi:** Nothing to disclose.

### Contemporary Lymphedema Management Among Insured U.S. Patients: Correlation of Disease Etiology With Treatment Choices



**Mark Iafrazi,** Thomas O'Donnell, Vascular Surgery, Tufts Medical Center

**Objective:** Lymphedema (LED) therapy aims to reduce edema and to improve function, comfort, and skin hygiene. These nonsurgical treatments can be categorized into conservative (CONS)—complex physical therapy with manual lymphatic drainage (MLD), massage, garments, and bandaging; and intermittent pneumatic compression with simple nonprogrammable pneumatic compression devices (SPCDs) or advanced programmable pneumatic compression devices (APCDs). We sought to define how frequently patients with a diagnosis of LED are provided LED-specific therapy and to determine what diagnoses are most commonly associated with advanced targeted LED therapies.

**Methods:** To determine the frequency of the various treatments of LED and their relationship to the cause of the LED, we queried claims for the years 2012 to 2016 from a deidentified Health Insurance Portability and Accountability Act-compliant commercial administrative insurance database with 165,000,000 members. We identified patients with an LED diagnosis code who had at least one inpatient or two outpatient claims filed with Blue Cross Blue Shield and who were enrolled in Blue Cross Blue Shield with continuous medical benefits for at least 12 months before and after the index date. Identified patients were then analyzed as to associated comorbidities and the treatments coded in these claims. Treatments were grouped as no treatment, CONS, SPCD, and APCD.

**Results:** We identified 81,366 patients with a diagnosis of LED, of whom 26,902 had sufficient continuous medical benefits to meet inclusion criteria; 5291 (19.7%) patients with a diagnosis of LED received no LED-specific treatment. CONS therapies alone were used in 17,387 (64.6%) of LED patients. Within this CONS group, 73% used MLD as a component of care. SPCD was the only pneumatic compression code entered for 680 (2.5%) patients, whereas the more advanced APCD codes were used in 3544 (13.2%) LED patients. Within each of these treatment groups, the Table